Metformin and N-terminal pro B-type natriuretic peptide in type 2 diabetes patients, a post-hoc analysis of a randomized controlled trial

What Was Tested

The paper reports a study of BNP (Nesiritide), published as a randomized controlled trial.

Patients with type 2 diabetes often have an elevated plasma level of N-terminal pro B-type as a marker of (sub) clinical cardiovascular disease.

Who Took Part

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

In a secondary analysis the researchers assessed a possible immediate treatment effect post baseline.

How the Study Was Run

The design is described as randomized and placebo-controlled.

Because people in this BNP (Nesiritide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

A placebo (an inactive look-alike) gave the BNP (Nesiritide) group a baseline to be compared against.

Plasma samples were drawn at baseline, 4, 17, 30, 43 and 52 months.

In a post-hoc analysis the researchers analyzed the change in NT-proBNP in both groups.

The researchers used a longitudinal mixed model analysis adjusting for age, sex and prior cardiovascular disease.

What Was Measured

Patients with type 2 diabetes often have an elevated plasma level of N-terminal pro B-type as a marker of (sub) clinical cardiovascular disease.

PubMed files the paper under topics including Cardiovascular Diseases, Diabetes Mellitus, Type 2, Metformin, Natriuretic Peptide, Brain and Peptide Fragments.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of BNP (Nesiritide).

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2021 (PloS one), a journal based in United States.

More context: the BNP (Nesiritide) compound page, all human trials.